PMID- 33996152
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 2090-0384 (Print)
IS  - 2090-0392 (Electronic)
VI  - 2021
DP  - 2021
TI  - Efficacy of ARB/HCTZ Combination Therapy in Uncontrolled Hypertensive Patients 
      Compared with ARB Monotherapy: A Meta-Analysis.
PG  - 6670183
LID - 10.1155/2021/6670183 [doi]
LID - 6670183
AB  - OBJECTIVE: To evaluate the efficacy of combination of angiotensin receptor 
      blocker (ARB) with hydrochlorothiazide (HCTZ) compared to ARB alone in patients 
      with uncontrolled hypertension via a systematic review and meta-analysis. 
      METHODS: We searched databases till July 2019 using relevant search terms. We 
      included articles that were randomised controlled trials (RCTs) comparing 
      ARB/HCTZ with ARB for a duration of at least 4 weeks and reported on the efficacy 
      or safety. Meta-analyses for efficacy outcomes were performed. In addition, 
      groups given different concentrations of HCTZ (12.5 and 25 mg) were analysed 
      separately. RESULTS: Sixteen RCTs (12,055 participants) were included. Overall, 
      ARB/HCTZ combination therapy (both 12.5 and 25 mg HCTZ combination) resulted in 
      better sitting systolic and diastolic blood pressure control than ARB alone (mean 
      difference (95% confidence interval (CI): -5.69 [-6.66, -4.73] for 12.5 mg and 
      -9.10 [-11.78, -6.42] for 25 mg and mean difference (95% CI): -2.91 [-3.31, 
      -2.51] for 12.5 mg and -4.16 [-4.75, -3.58] for 25 mg). ARB/HCTZ combination 
      therapy resulted in a higher rate of target blood pressure achievement compared 
      to ARB alone (risk ratio (95% CI): 1.50 [1.42, 1.59]). ARB/HCTZ combination 
      therapy had similar rates of total adverse events (AEs) and severe AEs compared 
      to ARB alone. CONCLUSION: ARB/HCTZ combination therapy is more efficacious for 
      controlling blood pressure, and combination with a low concentration of HCTZ has 
      similar AEs compared to ARB alone. Clinicians should consider adding HCTZ in the 
      medication regime of patients with uncontrolled hypertension using ARB, if their 
      clinical profile allows.
CI  - Copyright (c) 2021 Linlin Ma et al.
FAU - Ma, Linlin
AU  - Ma L
AD  - Department of Hypertension, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing, China.
FAU - Zheng, Keyang
AU  - Zheng K
AD  - Capital Medical University, Beijing, China.
FAU - Yan, Jiafu
AU  - Yan J
AD  - Capital Medical University, Beijing, China.
FAU - Cheng, Wenli
AU  - Cheng W
AUID- ORCID: 0000-0002-3176-0227
AD  - Department of Hypertension, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20210427
PL  - United States
TA  - Int J Hypertens
JT  - International journal of hypertension
JID - 101538881
PMC - PMC8096582
COIS- The authors declare that they have no conflict of interest.
EDAT- 2021/05/18 06:00
MHDA- 2021/05/18 06:01
PMCR- 2021/04/27
CRDT- 2021/05/17 06:11
PHST- 2020/10/26 00:00 [received]
PHST- 2021/04/01 00:00 [accepted]
PHST- 2021/05/17 06:11 [entrez]
PHST- 2021/05/18 06:00 [pubmed]
PHST- 2021/05/18 06:01 [medline]
PHST- 2021/04/27 00:00 [pmc-release]
AID - 10.1155/2021/6670183 [doi]
PST - epublish
SO  - Int J Hypertens. 2021 Apr 27;2021:6670183. doi: 10.1155/2021/6670183. eCollection 
      2021.